Iron formulations for topical administration and methods of treatment of iron deficiency
AssigneeDyve Biosciences, Inc.
InventorsRyan Beal, Luke Gonzales, Kilmar Martinez, Brandon Sand, Lisa Misell, Nathan Fitzsimmons
Life of this patent
Estimating the term…
Abstract
Provided herein are formulations for the transdermal administration of iron or an iron containing compound. Also provided are formulations that include iron chelators and antioxidants, and methods of using the formulations provided herein for the treatment of diseases and disorders relating to iron deficiency, anemia, and conditions associated with anemia.
Claims21
-20. (canceled)
A formulation for transdermal delivery of one or more iron-containing compounds through the skin of a subject, the formulation comprising:
- an iron-containing compound;
- an iron chelator;
- an antioxidant;
- and
- one or more of the following:
- almond oil, Cetiol® Ultimate, cetyl alcohol, citric acid, cyclohexane, Durosoft, glacial acetic acid, H2O, HP beta-CD, lecithin, Phospholipon® 90G, Poloxamer 407, propanoic acid, stearic acid, Tego 13-06, titanium dioxide, and triacetin.
A formulation for transdermal delivery of one or more iron containing compounds through the skin of a subject, comprising:
- an iron containing compound comprising ferrous sulfate in an amount from about 3.0% to about 40.0% w/w;
- Phospholipon® 90G in an amount from about 5.0% w/w to about 15.0% w/w;
- cetyl alcohol in an amount from about 1.0% w/w to about 5.0% w/w;
- stearic acid in an amount from about 0.5% w/w to about 5.0% w/w;
- triacetin in an amount from about 5.0% w/w to about 25.0% w/w;
- lecithin in an amount from about 1.0% w/w to about 10.0% w/w;
- almond oil in an amount from about 3% w/w to about 15.0% w/w;
- Cetiol® Ultimate in an amount from about 3.0% w/w to about 20.0% w/w;
- Poloxamer 407 in an amount from about 2.0% w/w to about 20.0% w/w;
- glacial acetic acid in an amount from about 2.0% w/w to about 10.0% w/w;
- propanoic acid in an amount from about 1.0% w/w to about 5.0% w/w;
- cyclohexane in an amount from about 2.0% w/w to about 10.0% w/w;
- Tego 13-06 in an amount from about 2.0% w/w to about 10.0% w/w;
- Durosoft® PK-SG in an amount from about 0.5% w/w to about 3.0% w/w;
- and
- H2O to complete;
- and
- optionally comprising one or more of
- HP beta CD in an amount up to about 1.0% w/w;
- citric acid in an amount up to about 5.0% w/w;
- vitamin C in an amount up to about 5.0% w/w;
- vitamin E in an amount up to about 5.0% w/w;
- EDTA in an amount up to about 20.0% w/w;
- and
- titanium dioxide in an amount up to about 5.0% w/w.
A formulation for transdermal delivery of one or more iron containing compounds through the skin of a subject, comprising:
- an iron containing compound comprising ferrous sulfate in an amount from about 3.0% to about 40.0% w/w;
- Phospholipon® 90G in an amount from about 0.0% to about 15.0% w/w;
- cetyl alcohol in an amount from about 0.0% to about 5.0% w/w;
- stearic acid in an amount from about 0.0% to about 5.0% w/w;
- triacetin in an amount from about 0.0% to about 40.0% w/w;
- lecithin in an amount from about 0.0% to about 10.0% w/w;
- almond oil in an amount from about 0.0% to about 15.0% w/w;
- Cetiol® Ultimate in an amount from about 0.0% to about 20.0% w/w;
- Poloxamer 407 in an amount of from about 0.0% to about 20.0% w/w;
- glacial acetic acid in an amount from about 0.0% to about 10.0% w/w;
- propanoic acid in an amount from about 0.0% to about 5.0% w/w;
- cyclohexane in an amount from about 0.0% to about 10.0% w/w;
- tego 13-06 in an amount from about 0.0% to about 10.0% w/w;
- Durosoft® PK-SG in an amount from about 0.0% to about 3.0% w/w;
- HP beta CD in an amount from about 0.0% to about 1.0% w/w;
- citric acid in an amount from about 0.0% to about 5.0% w/w;
- vitamin C in an amount from about 0.0% to about 5.0% w/w;
- vitamin E in an amount from about 0.0% to about 5.0% w/w;
- EDTA in an amount from about 0.0% to about 20.0% w/w;
- titanium dioxide in an amount from about 0.0% to about 5.0% w/w;
- and water to complete.
Dependencies are inferred from the claim text.